Your browser doesn't support javascript.
loading
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen; Ramanathan, Ramesh K; Adjei, Alex A; Fong, Peter C; Shapira-Frommer, Ronnie; Tawbi, Hussein A; Rubino, Joseph; Rush, Thomas S; Zhang, Da; Miselis, Nathan R; Samatar, Ahmed A; Chun, Patrick; Rubin, Eric H; Schiller, James; Long, Brian J; Dayananth, Priya; Carr, Donna; Kirschmeier, Paul; Bishop, W Robert; Deng, Yongqi; Cooper, Alan; Shipps, Gerald W; Moreno, Blanca Homet; Robert, Lidia; Ribas, Antoni; Flaherty, Keith T.
Afiliação
  • Moschos SJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Sullivan RJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Hwu WJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ramanathan RK; Translational Genomics Research Institute, Phoenix, Arizona, USA; Virginia G. Piper Cancer Center, Scottsdale, Arizona, USA.
  • Adjei AA; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Fong PC; The University of Auckland and Auckland City Hospital, Auckland, New Zealand.
  • Shapira-Frommer R; Department of International Medicine, Chaim Sheba Medical Center, Tel-HaShomer, Israel.
  • Tawbi HA; University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
  • Rubino J; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Rush TS; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Zhang D; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Miselis NR; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Samatar AA; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Chun P; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Rubin EH; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Schiller J; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Long BJ; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Dayananth P; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Carr D; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Kirschmeier P; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Bishop WR; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Deng Y; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Cooper A; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Shipps GW; Merck & Co. Inc., Kenilworth, New Jersey, USA.
  • Moreno BH; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA.
  • Robert L; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA.
  • Ribas A; Jonsson Comprehensive Cancer Center at UCLA, University of California Los Angeles, Los Angeles, California, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
JCI Insight ; 3(4)2018 02 22.
Article em En | MEDLINE | ID: mdl-29467321
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Piridinas / Pirrolidinas / Triazóis / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Indazóis / Neoplasias Tipo de estudo: Etiology_studies Idioma: En Revista: JCI Insight Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Piridinas / Pirrolidinas / Triazóis / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Indazóis / Neoplasias Tipo de estudo: Etiology_studies Idioma: En Revista: JCI Insight Ano de publicação: 2018 Tipo de documento: Article